Newsroom

NEWS

July 28, 2026

Galux Appoints Taeyong Park as Co-CEO, Transitioning to Co-CEO Structure with Chaok Seok

Read More

NEWS

May 28, 2026

Galux and AimedBio Partner to Advance Next-Generation Therapeutics

Read More

NEWS

May 19, 2026

Galux Shows Broadest Target Coverage in Comparative De Novo Antibody Design Study

Read More

NEWS

April 21, 2026

GC Biopharma and Galux Collaborate on AI-designed Autoimmune Antibody Drugs

Read More

NEWS

April 20, 2026

OliX and Galux Partner to Develop AI-based siRNA Delivery Platform

Read More

NEWS

April 15, 2026

Galux to Present Preclinical Data on AI-Designed PD-1/IL-18v Immunocytokine at AACR 2026

Read More

NEWS

February 10, 2026

Galux Raises $29M Series B to Advance AI-Driven Protein Design for Drug Discovery

Read More

NEWS

February 9, 2026

ISU Abxis and Galux Launch AI-Driven Collaboration to Develop Next-Generation Therapies for Rare Diseases

Read More

NEWS

December 17, 2025

Galux Announces Research Agreement with Boehringer Ingelheim to Advance AI-Driven Protein Design

Read More

NEWS

December 11, 2025

Galux and Seoul National University Develop ‘T-SCAPE,’ an AI for Predicting Immunogenicity of Drug Candidates

Read More

NEWS

December 2, 2025

Galux and Celltrion Enter Strategic Partnership to Co-Develop Next-Generation Multispecific Antibodies for Autoimmune Diseases

Read More

NEWS

November 26, 2025

Galux Achieves Breakthrough by Delivering High-Affinity De Novo Antibodies from Only 50 AI Designs, Marking a New Era in Precision Protein Design

Read More